Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) Receives $18.67 Average PT from Brokerages

Artiva Biotherapeutics, Inc. (NASDAQ:ARTV) has been assigned a consensus recommendation of “Moderate Buy” from the five analysts that are presently covering the firm, Marketbeat reports. One analyst has rated the stock with a sell recommendation, three have given a buy recommendation and one has issued a strong buy recommendation on the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $18.6667.

A number of equities analysts recently weighed in on the stock. Needham & Company LLC restated a “buy” rating and set a $18.00 target price on shares of Artiva Biotherapeutics in a research report on Wednesday, March 11th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Artiva Biotherapeutics in a report on Tuesday, January 27th.

Institutional Investors Weigh In On Artiva Biotherapeutics

Several large investors have recently made changes to their positions in the company. Prelude Capital Management LLC bought a new position in Artiva Biotherapeutics during the third quarter valued at approximately $41,000. Bank of America Corp DE increased its stake in Artiva Biotherapeutics by 225.8% in the 3rd quarter. Bank of America Corp DE now owns 16,145 shares of the company’s stock worth $46,000 after acquiring an additional 11,190 shares during the last quarter. Bridgeway Capital Management LLC bought a new stake in Artiva Biotherapeutics in the 2nd quarter worth approximately $53,000. Qube Research & Technologies Ltd purchased a new stake in shares of Artiva Biotherapeutics during the 2nd quarter worth approximately $58,000. Finally, Jane Street Group LLC bought a new position in shares of Artiva Biotherapeutics during the 2nd quarter valued at approximately $67,000.

Artiva Biotherapeutics Trading Down 0.1%

NASDAQ ARTV opened at $6.74 on Friday. The stock’s 50 day moving average is $5.10 and its 200 day moving average is $4.23. Artiva Biotherapeutics has a 12 month low of $1.47 and a 12 month high of $7.75. The stock has a market cap of $166.61 million, a PE ratio of -1.97 and a beta of 1.46.

Artiva Biotherapeutics (NASDAQ:ARTV) last posted its quarterly earnings results on Tuesday, March 10th. The company reported ($0.84) earnings per share for the quarter, topping the consensus estimate of ($0.87) by $0.03. On average, analysts forecast that Artiva Biotherapeutics will post -4.95 EPS for the current fiscal year.

About Artiva Biotherapeutics

Artiva Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the development of allogeneic “off-the-shelf” cell therapies for cancer. The company’s proprietary platform leverages natural killer (NK) cells engineered to express chimeric antigen receptors (CARs) or other targeting modalities, with the goal of delivering potent anti-tumor activity while minimizing the safety and supply limitations associated with patient-derived (autologous) approaches.

Artiva’s pipeline includes multiple lead product candidates designed to address both hematologic malignancies and solid tumors.